Patent Thickets, Interchangeability of biosimilars, Clinical Trials exemption for biosimilars, "Net Effective Cost" PBM reform, Country of Origin labeling, Abbreviated Drug Labeling, Tariffs, Domestic Manufacturing, DSCSA.
2026 · 2nd Quarter (Apr 1 - June 30)
LUPIN PHARMACEUTICALS INC
Filed by LUPIN PHARMACEUTICALS INC.
Open official filingSource-reported fields
Filing overview
- Type
- 2nd Quarter - Report
- Posted
- Jul 24, 2026
- Income
- Not reported
- Expenses
- $80,766.00
- Registrant
- LUPIN PHARMACEUTICALS INC
- Filing UUID
- 40cf1d3f-f22e-4083-a03e-a643e969b982
- Termination date
- Not reported
Expense method: A
Literal source text
Lobbying issues and bill citations
Reimbursement of generic pharmaceuticals and biosimilars.
Country of Origin labeling.
Incentivizing domestic manufacturing of essential medicines.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.